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Conclusions: Despite treating pf9, with more complex anatomy. RooPro 
use is a990clated with a 69% reduction In CK rise. ?..2% lower Incidence of 
mild CK nso and a reduction of large non.Q wave Ml's by 75%, 
1088-103 ] Abclxlmeb Inhibits Formetlon ot Platelet-derlved 
MlcmparUclea Despite Pletalat Activation 
M,G, Treuth. S, Simon. T. Chow. C.W, Smith, N.S. Klelman, BnylorCollogo 
of Mettle/rio, Hou.~ton. TX, USA 
Pl~telotoderlved micropnrllolos (PMP), pl~telat (P) membrane vesicles with 
pro¢oogul~nt prope~lles, form after P activation, Abqlxlmsb (7E3). ~ mon- 
o01on~l ~ntlbody against GP IIb.lll~. Inhibits P aggrog~tlon ~nd reduee~ 
complications of PTGA, Using whole blood flow cytomeffy, we studied ft~e 
formation el PMP In psflents meelvtng 7E3 during PTCA, Blood collected 
before and one hr after A wa~ eflm|~hllod with ADP or a strong agonlsf, 
thrombln receptor ~¢tlv~flng peptlde (TRAP), 7E3 bound 93% of at:riveted 
IIb.tll~ receptors before and 7~=81% alter stimulation, P.solccfln. an Indtca. 
for of P a~tlvetton, increased 8,7 and 10.3 fold with AOP (p ,  0,01), and 164 
and 18,t fold with TRAP (p ~ 0,00t PMP (%) worn: 
BB~alin~ 5~+M ADP ~9+,M AOP 5~.M TRAP ~O++M TRAP 
P~)~I ?E3 ~41es 11~111 I~t  t,~ ~I~ ~31 1.t 
P 00~ COl 00~ el4 O0S 
PMP were inversely proportional fo unbarred lib.Ilia mcepfera (r = 039, 
p = 0,005), Thu,'~ 7E3 inhibits PMP form~fion ~ftsr we~k slimulatlen but 
l~rmCfs some PMP formation ~fter morn infanso stimulation, Limiting PMP 
m~y represent anofhor mn(:h~ntsm by which "~E3 prevents thrombosis and 
m~y h~ve Impllclations for lib/Ilia antagonisfs In Coronary syndromes whom 
thmmbln provides an Inton~o sfimulus for P activation end PMP fermafion, 
• Synargy of Abolxlmsb and Tlclopldlne In 
Patients Undergoing Intracoronary Stentlng 
N,~, Klelman, N, Grat.ladoi, E, Lance, K, Mamsh, J. Taylor, J. Higglnbotham, 
A, Edwards, M,B, Effmn, M,A, Mascelli, R,E, Jordan, BaylorCoflege of 
Me¢ltctne, Houston. T+~,qnd Centocor In[',, Mah,Pm, P~, USA 
TIclopldlne iT) and abcixlmab (abx) exhibit different pharmacadynamtc pro- 
files and both are often usod during slant placement, To study their inferaction, 
we measured Inhibition of platelet aggregation (IPA) to 5 ~M ADP and 8 ~=M 
TRAP, and GP lib-Ilia receptor blockade (RB) in patient9 receiving steels. All 
paftent9 received nspinn end T 12-18 hours prior to PTCA; half also mcoivod 
abx immediately peer. ]'ime wee moasurod from abx administrabon. IPA for 
ADP was: 
Po.~t T 2 H 24 H 3 ID 713 14 D 
T 4. obx 7 t 8 94 ~ 2 64 .t 4 49 t" 6 47 '~ 13 43 ~ 12 
T 11.16 10:16 1S~9 25±8 4S~14 21±13 
P 0,01 000008 00042 064 0,45 038 
In response fo TRAP, IPA for T + abx was less profound, peaking at 47% 
at bye hours, and falling to 13% at 3 days and 22% at 14 days, compared 
with 6%, 4%, 1% re9pecfively for T only. RB at 2 hrs was 90% for T + abx and 
declined to baseline 81 14 days. T alone led to minimal change in RB. Thus, 
the combination of T and abx allowed profound inltnl IPA compared with 
T alone; pit aggregation Mmained inhibited even when receptor availability 
Mtumod to beeolino. Abx hod little effect on the late action of 3. Theso 
findings provide mechanistic support for the simultaneous use of T and abx 
1 088-105 ] Incidence of Bleeding Complications Associated 
With Abclxlmab Huse In Con[unction With 
Thrombolytlo Therapy In Patients Requiring 
Angioplasty 
D.W Sundlof, P. Reprkpatfanspitet, N Wongpraparut, P. Pathi. M.N, Keller. 
LE. Jacobs, S. Yazdanfar Albert Einstein Medical Center. Philadelphia. PA. 
USA 
Background: With the more widespread use of Abciximab (Abx) as an adjunct 
to angiopla9ty (PTCA) during acute myocardial infarction (MI). the safety of 
the combination therapy of thrombolytics and abx should be more clearly 
defined. 
Methods: A retrospective analysis was performed in 100 acu', " ~! p~.t!c."*.s 
who unde=~vent PTCA with adjunctive Abx therapy. Patients were divided ;eta 
three groups: A (Rescue PTCA within 15 hr of thrombolytics) n = 22, B (suc- 
cessful thrombolytictherapy followed by elective PTCA) n = 34. and C (primary 
PTCA) n = 44. All patient8 received Abx 89 a 0.25 mg/kg bolus followed by an 
Infusion of 101~g/rain for 12 hours. Bleedin9 was classified 88 major, miner, or 
insignificant according to the criteria of the TIMI Study Group. 
Results: 
Group A Group B Group C 
tnsigniflcnnt Bleed 14 (64%) 31 (91%) 33 (75%) 
Minor ble~,d 4 (18%) 3 (9%) 10 (~3%) 
Meier bleed 4 (18%) 0 t (2%) 
Major bleeding occurred ream frequently In group A versus group B (p 
~: 0,02) end group C (p .~ 0,04), Two intragraninl hemormagos occurred in 
group A only. 
Conclusion: There is n significant incre~se ,n m~lor b t~ ing  complications 
whoa Aboixim~b Is used In conlunolien with 'rescue ¢ngiop!~sty" within 15 
hr after f~iled Ihrombolyti¢ therapy, 
~ "Bailout n e?E30ur lng Comna~/ Intervent ion:  
Aq=ute Results end Long-term !+OllOw,up 
D,E, Rshmsnn, JA+ Krupp, B+ Go!d0erg, M,P, Savage+ Jefferson Me~/i~l 
Collage. Phit~cletphla, ~nns.t,tvam~. US4 
Prier studios have 6hawr the efficacy of C?E3 in decreasing ischemie compli, 
Cations when given immediately pear 1o ." TCA The purpose of this study was 
to avail.late the efficacy of "bailout" c7E3 on acute and Iong.tem~ oulcoale 
after coronary intervention, 95 patients undenNent corona~ intervention w~th 
~diunctiv8 7E3; 58 patients treated pmphylact~e!ly, and 3? patients fwated 
provist0nally for s~baptimal response to initial intervention (bailout), Proce- 
dural Su~-'ess was achieved in all 37 bailout patients (10(]%). There weM 
no tn.ho9pifal desfhs, Q.MI, CABG or repast PTCA: ~ patmnts e~tpefleeced 
non Q.MI (5.4%), Comparison of the prophylactic and bailout c7E3 patients 
demonstrated no significant difference in in.hospital cardiP.~- compbcations 
(3,4 va 5,4%) or vascular complications (10.3 vs 5,4%). Late clin¢..al fol- 
low-up at ~_1 year (range 13--28 months) was obtained in all 37 bailout 
patients (see table), 
Death CABG MI RePTCA Any Event 
30 day 0 0 2 (54%) O ;~ t54%) 
: 1 yeast 1 t~ 7%) 2 (54%t 2 t54%) tO (~7~ot 15 (40.5%) 
Following hospital discharge, them were no cardiac events in bailout 
patients within 30 days. However. late follow-up revealed cardiac events 
in 15 (40,5%) pabents predominantly due to clinical mstenosis and repeat 
Mvascutanzation, 
Conclusions: Use of c7E3 in a bailout fashion is associated w=th igh 
procedural success, m-hospital outcomes comparable to prophylactic use, 
and a low 30 day cardiac event rate. However, the potential tar late restenosts 
is not eliminated. Further prospective foals of this strategy aM needed 
1~8~ Initial Report of Gamma Radiotherapy for  Diffuse 
" Coronary Restenosla: The SCRIPPSll Trials 
Paul S Teirsteln, Vincent Massullo, Shirish Jani, Jeffrey J. Popma, Robert 
J, Ruses, Stephen Steutennan. Shela Norman, Martin B. Leon. 
Prbkahar Tnp~-anemL Scripps Clinic. La Jells. CahfoMia. USA 
Gamma radiatit.n has been shown to reduce coronary restenosis in patients 
with discrete (d30 ram) lesion lengths. In a subsequent rial (the SCRIPPS II 
Trial), we randomized 51 patients with diffuse restenotic segments up to 65 
mm in lesion length A blind lumen radiation delivery catheter was used to 
lesion, 
It- 192 Placebo 
n=26 n=25 
Lesion length (mm) 1607 ± 12.43 13.91 ± 7.48 NS 
Length. 10 mm 56% 60"0 NS 
Vessel diameter ( am) 249 ± 045 2.56 • 0.50 NS 
MLD Pre (mm) 0 70 ± 0.45 0.61 ± 0.37 NS 
MLO Post (ram) 2.74 ± 0.45 295 ± 053 NS 
DoathlMI/CABG O/O/O Ot0tO 
In 2 patients, the study catheter partially obstructed flow resulting in 
significant ischemia requiring interruption of treatment. In both cases the 
source wire was withdrawn in < 20 seconds. 
Conclusion: Coronary ischemia may occur dudng gamma irradiation of 
diffuse, small vessel di.~a.qe, but catheters can be quickly withdrawn with- 
out jeopardizing patient safety. Interim analysis of 6-month outcome will be 
presented. 
